354 related articles for article (PubMed ID: 19387994)
1. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
2. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
4. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
5. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
Locatelli I; Kastelic M; Koprivsek J; Kores-Plesnicar B; Mrhar A; Dolzan V; Grabnar I
Eur J Pharm Sci; 2010 Oct; 41(2):289-98. PubMed ID: 20599499
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
9. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
Bozina N; Jovanović N; Lovrić M; Medved V
Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of paliperidone versus risperidone.
de Leon J; Wynn G; Sandson NB
Psychosomatics; 2010; 51(1):80-8. PubMed ID: 20118446
[TBL] [Abstract][Full Text] [Related]
12. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
[TBL] [Abstract][Full Text] [Related]
13. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
Barteček R; Juřica J; Zrůstová J; Kašpárek T; Pindurová E; Žourková A
Neuro Endocrinol Lett; 2012; 33(2):236-44. PubMed ID: 22592207
[TBL] [Abstract][Full Text] [Related]
14. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Troost PW; Lahuis BE; Hermans MH; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
J Clin Psychopharmacol; 2007 Feb; 27(1):52-7. PubMed ID: 17224713
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
16. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
[TBL] [Abstract][Full Text] [Related]
17. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
[TBL] [Abstract][Full Text] [Related]
18. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
20. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
